Rubicon Research Stock Screener | Share Price & Fundamental Analysis
RUBICON
Pharmaceuticals
Share Price NSE
₹819.75
▼
-16.35 (-1.96%)
Share Price BSE
₹819.60
▼
-16.85 (-2.01%)
As of April 13, 2026, the Rubicon Research share price (NSE: RUBICON) is ₹819.75 on NSE and ₹819.60 on BSE, down 1.96% from the previous close, with shares trading between ₹815.00 and ₹830.70, and a 52-week range of ₹577.25–₹856.20.
Browse RUBICON cash flow statement to support your investment research.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Rubicon Research Market Cap
₹13,774.77 Cr.
RUBICON P/E Ratio (TTM)
68.39
Rubicon Research P/B Ratio
12.29
EPS (TTM)
₹8.82
Dividend Yield
-
Debt to Equity
0.91
RUBICON 52 Week High
₹856.20
Rubicon Research 52 Week Low
₹577.25
Operating Margin
23.00%
Profit Margin
15.24%
RUBICON Revenue (TTM)
₹479.00
EBITDA
₹112.00
Net Income
₹73.00
Total Assets
₹1,451.00
Total Equity
₹541.00
Rubicon Research Share Price History - Stock Screener Chart
Screen RUBICON historical share price movements with interactive charts. Analyze price trends and patterns.
Rubicon Research Company Profile - Fundamental Screener
Screen Rubicon Research company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for RUBICON shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE506V01022
Rubicon Research Balance Sheet Screener
Screen RUBICON balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 1,451 | 1,110 | 750 | 560 | 538 | 430 |
| Current Assets | 1,063 | 763 | 502 | 328 | 340 | 265 |
| Fixed Assets | 327 | 307 | 199 | 193 | 188 | 157 |
| Liabilities | ||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 124 | 152 | 102 | 71 | 53 | 12 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 541 | 385 | 286 | 305 | 374 | 341 |
| Share Capital | 15 | 15 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 526 | 370 | 281 | 300 | 369 | 335 |
Rubicon Research Income Statement Screener - Profit & Revenue Analysis
Screen Rubicon Research income statement and profit fundamentals.
Analyze RUBICON quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Rubicon Research share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|
| Revenue | 479 | 413 | 353 | 358 | 314 | 299 | 317 |
| Expenses | 367 | 318 | 273 | 286 | 244 | 234 | 257 |
| EBITDA | 112 | 95 | 80 | 73 | 70 | 64 | 61 |
| Operating Profit % | 23.00% | 23.00% | 22.00% | 20.00% | 22.00% | 21.00% | 19.00% |
| Depreciation | 12 | 12 | 10 | 10 | 9 | 8 | 9 |
| Interest | 10 | 11 | 11 | 12 | 8 | 7 | 10 |
| Profit Before Tax | 91 | 72 | 60 | 51 | 53 | 49 | 41 |
| Tax | 18 | 18 | 16 | 15 | 15 | 15 | 16 |
| Net Profit | 73 | 54 | 43 | 36 | 38 | 35 | 26 |
| EPS | 4.46 | 3.49 | 2.81 | 2.35 | 2.50 | 2.27 | 1.66 |
Rubicon Research Cash Flow Screener - Liquidity Fundamentals
Screen RUBICON cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
| Operating Activities | 159 | 21 | -75 | -63 | 62 | 6 |
| Investing Activities | -65 | -68 | -32 | -46 | -46 | -84 |
| Financing Activities | -40 | 44 | 123 | 63 | 52 | 80 |
| Net Cash Flow | 54 | -4 | 16 | -46 | 67 | 1 |
Rubicon Research Shareholding Pattern Screener
See Rubicon Research shareholding pattern with promoter, FII, and DII holdings.
Check Rubicon Research promoter holding and ownership changes for RUBICON on TickJournal.
| Item | 2025-Sept | 2025-Oct | 2025-Dec | 2024-Jul |
|---|---|---|---|---|
| Promoter Holding | 59.99% | 59.99% | 59.99% | 84.15% |
| FII Holding | 9.37% | 9.37% | 7.99% | 0.00% |
| DII Holding | 10.54% | 10.54% | 9.45% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 18.28% | 18.28% | 2.71% | 0.00% |
| Other Holding | 1.82% | 1.82% | 19.86% | 15.85% |
| Shareholder Count | 105,311 | 105,311 | 31,914 | 15 |
Rubicon Research Share Dividend Screener - Share Yield Analysis
Check Rubicon Research dividend history with payout and yield data.
View Rubicon Research dividend details including ex-dates and amounts for RUBICON stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.02 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Rubicon Research Stock Index Membership
See which indices include Rubicon Research stock.
Check RUBICON index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Rubicon Research Market Events Screener - Corporate Actions
Get Rubicon Research corporate actions including splits, bonuses, and buybacks.
Check Rubicon Research stock events that may affect RUBICON share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | 5.98% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -1.76% |
Rubicon Research Competitors Screener - Peer Comparison
Screen RUBICON competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 397,066 | 37.62 | 54,729 | 9.71% | 10,980 | 34.03 |
| Divis Laboratories | 162,374 | 63.80 | 9,712 | 18.67% | 2,191 | 53.67 |
| Torrent Pharmaceuticals | 140,631 | 60.97 | 11,539 | 6.99% | 1,911 | 47.83 |
| Lupin | 106,665 | 22.48 | 22,910 | 13.74% | 3,306 | 57.51 |
| Dr Reddys Laboratories | 102,845 | 18.32 | 33,741 | 16.73% | 5,725 | 45.58 |
| Cipla | 99,317 | 21.81 | 28,410 | 7.12% | 5,291 | 40.75 |
| Zydus Life Science | 92,111 | 18.06 | 23,511 | 18.55% | 4,615 | 57.32 |
| Mankind Pharma | 85,822 | 47.03 | 12,744 | 20.90% | 2,007 | 51.63 |
| Aurobindo Pharma | 78,373 | 22.33 | 32,346 | 9.43% | 3,484 | 65.82 |
| Alkem Laboratories | 65,043 | 26.50 | 13,458 | 3.70% | 2,216 | 53.68 |
Rubicon Research Company Announcements - News Screener
Screen RUBICON latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-31 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-03-31 | Closure of Trading Window | - |
| 2026-03-16 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-03-16 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-13 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-05 | Newspaper Publication - Financial Results | - |
| 2026-02-03 | General Updates | - |
| 2026-02-03 | Announcement Under Regulation 30 - Appointment Of Secretarial Auditor | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-02-03 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday February 03 2026 | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-02-03 | Results - Financial Results For 31-12-2025 | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-01-30 | Intimation Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-01-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-27 | Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Will Be Held On Tuesday 03Rd February 2026 Inter-Alia To Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 3 | - |
| 2026-01-14 | Announcement under Regulation 30 (LODR)-Acquisition | - |